A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: Role of BRCA1.
Citation:
Stordal, B. and Davey R, A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: Role of BRCA1., Current Cancer Drug Targets, 9, 3, 2009, 354 - 365Download Item:
Abstract:
A systematic review of cell models of acquired drug resistance not involving genetic
manipulation showed that 80% of cell models had an inverse resistance relationship
between cisplatin and paclitaxel[1]. Here we systematically review genetically
modified cell lines in which the inverse cisplatin/paclitaxel resistance phenotype has
resulted. This will form a short list of genes which may play a role in the mechanism
of the inverse resistance relationship as well as potential markers for monitoring the
development of resistance in the clinical treatment of cancer. The literature search
revealed 91 genetically modified cell lines which report toxicity or viability/apoptosis
data for cisplatin and paclitaxel relative to their parental cell lines. This resulted in 26
genes being associated with the inverse cisplatin/paclitaxel phenotype. The gene with
the highest number of genetically modified cell lines associated with the inverse
resistance relationship was BRCA1 and this gene is discussed in detail with reference
to chemotherapy response in cell lines and in the clinical treatment of breast, ovarian
and lung cancer. Other genes associated with the inverse resistance phenotype
included dihydrodiol dehydrogenase (DDH) and P-glycoprotein. Genes which caused
cross resistance or cross sensitivity between cisplatin and paclitaxel were also
examined, the majority of these genes were apoptosis associated genes which may be
useful for predicting cross resistance. We propose that BRCA1 should be the first of a
panel of cellular markers to predict the inverse cisplatin/paclitaxel resistance
phenotype.
Author's Homepage:
http://people.tcd.ie/stordalbDescription:
PUBLISHED
Author: STORDAL, BRITTA KRISTINA
Publisher:
Bentham ScienceType of material:
Journal ArticleSeries/Report no:
Current Cancer Drug Targets;9, 3Availability:
Full text availableKeywords:
Cisplatin, Paclitaxel, BRCA1Metadata
Show full item recordLicences: